NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV formulation of suramin. According to the announcement, the company has completed execution of three pivotal registration/validation batches of PAX-101. The company noted that the completion is an “important milestone” in enabling a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (FDA), which it plans to complete by the last quarter of 2024. The NDA, along with the approval of the FDA, is a strategic step in the company’s efforts…







